Abstract
New designer drugs (synthetic cannabinoids and synthetic cathinones) are new “legal highs” that are sold online for recreational public or private use.
Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law.
Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts.
Designer drugs are often labeled as “not for human consumption” to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.
There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
Keywords: Synthetic cannabinoids, synthetic cathinones, legal highs, recreative drugs.
Current Pharmaceutical Design
Title:New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature
Volume: 20 Issue: 25
Author(s): Olivier Cottencin, Benjamin Rolland and Laurent Karila
Affiliation:
Keywords: Synthetic cannabinoids, synthetic cathinones, legal highs, recreative drugs.
Abstract: New designer drugs (synthetic cannabinoids and synthetic cathinones) are new “legal highs” that are sold online for recreational public or private use.
Synthetic cannabinoids are psychoactive herbal and chemical products that mimic the effects of cannabis when used. These drugs are available on the Internet or in head shops as incense or air fresheners to circumvent the law.
Cathinone is a naturally occurring beta-ketone amphetamine analog found in the leaves of the Catha edulis plant. Synthetic cathinones are phenylalkylamine derivatives that may possess amphetamine-like properties. These drugs are sold online as bath salts.
Designer drugs are often labeled as “not for human consumption” to circumvent drug abuse legislation. The absence of legal risks, the ease of obtaining these drugs, the moderate cost, and the availability via the Internet are the main features that attract users, but the number of intoxicated people presenting with emergencies is increasing.
There is evidence that negative health and social consequences may affect recreational and chronic users. The addictive potential of designer drugs is not negligible.
Export Options
About this article
Cite this article as:
Cottencin Olivier, Rolland Benjamin and Karila Laurent, New Designer Drugs (Synthetic Cannabinoids and Synthetic Cathinones): Review of Literature, Current Pharmaceutical Design 2014; 20 (25) . https://dx.doi.org/10.2174/13816128113199990622
DOI https://dx.doi.org/10.2174/13816128113199990622 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Contemporary Review of Drugs Used to Treat Obesity
Cardiovascular & Hematological Agents in Medicinal Chemistry Peri-Procedural Care of Renal Nerve Ablation Candidates
Current Clinical Pharmacology Advanced Therapies For End-Stage Heart Failure
Current Cardiology Reviews T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design MicroRNAs Determining Inflammation as Novel Biomarkers and Potential Therapeutic Targets
Current Medicinal Chemistry The Effect of Anti-B-cell Therapy on the Development of Atherosclerosis in Patients with Rheumatoid Arthritis
Current Pharmaceutical Design Lost in Translation: What is Limiting Cardiomyoplasty and Can Tissue Engineering Help?
Current Stem Cell Research & Therapy Circadian Variation of Cardiovascular Events and Morning Blood Pressure Surge
Vascular Disease Prevention (Discontinued) New Insights into the Pleiotropic Effects of Statins for Stroke Prevention
Mini-Reviews in Medicinal Chemistry Propofol and Systemic Inflammatory Response in Abdominal Aortic Surgery
Letters in Drug Design & Discovery Indications, Implications and Applications of Renal Denervation. Have we Discovered Something new?
Current Hypertension Reviews Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Fluorescein Fluorescence Use in the Management of Intracranial Neoplastic and Vascular Lesions: A Review and Report of a New Technique
Current Drug Discovery Technologies Molecular Imaging of Vascular Inflammation
Current Pharmaceutical Design Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Sestrins: A New Kid for Stroke Treatment?
Current Drug Delivery CD36 as a Therapeutic Target for Endothelial Dysfunction in Stroke
Current Pharmaceutical Design Multi-scale LBP and SVM Classification to Identify Diabetic Retinopathy in Lesions
Current Medical Imaging Calcium Channel Blockade and Peroxisome Proliferator Activated Receptor γ Agonism Diminish Cognitive Loss and Preserve Endothelial Function During Diabetes Mellitus
Current Neurovascular Research Late-Onset Glycogen Storage Disease Type 2
Current Molecular Medicine